Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen

Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen

OBJECTIVE: To study if metformin, when administered to first-degree relatives of type 2 diabetes mellitus subjects who have metabolic syndrome and normal glucose tolerance, could improve the cardiovascular risk profile and reduce the levels of both C-reactive protein and fibrinogen. INTRODUCTION: Me...

Full description

Bibliographic Details
Main Authors: Luis Mauro Alvim de Lima, Nicolas Wiernsperger, Luiz Guilherme Kraemer-Aguiar, Eliete Bouskela
Format: Article
Language:English
Published: Faculdade de Medicina / USP 2009-05-01
Series:Clinics
Subjects:
Metformin
Fibrinogen
C-reactive protein
Normoglycemia
Metabolic syndrome
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000500008

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000500008

Similar Items